Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Molecular Signatures of Early-Onset Neonatal Sepsis in Umbilical Cord Blood

Award Number: K23AI139337
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP
PERIOD OF PERFORMANCE START DATE: 02/04/2019
PERIOD OF PERFORMANCE END DATE: 01/31/2025

Group Awards By:

View Award Description

Molecular Signatures of Early-Onset Neonatal Sepsis in Umbilical Cord Blood - PROJECT SUMMARY Early-onset sepsis (EOS) due to invasive bacterial infection is a leading cause of morbidity in infants and disproportionately affects those born preterm. Accurate diagnosis of EOS remains inadequate. The low sensitivity and delayed time to culture results combined with the poor predictive values of available laboratory markers leads to our inability to rule-out EOS. Thus, infants are exposed to extended duration broad-spectrum empiric antibiotics, which have serious associated adverse consequences such as necrotizing enterocolitis, antibiotic resistant infections, and an altered microbiome. The proposed research will apply proteomics to identify gestational age-specific umbilical cord blood markers toward development of a proposed diagnostic tool with strong negative risk prediction for EOS. Cord blood is promising to identify EOS as it reflects the intrauterine environment where infection originates in preterm birth. In previous work, we found that inflammatory proteins serum amyloid A, C-reactive protein and haptoglobin are substantially elevated in cord blood of preterm infants with culture-confirmed EOS. These data inform our hypothesis that a combination of cord blood proteins provides a signature to differentiate impending EOS and uninfected states. Archived cord blood from infants in an existing longitudinal cohort will be used in a nested case-control design. Aim 1 will measure the cord blood proteome of uninfected infants (controls) across gestational ages using an untargeted proteomics approach to characterize the developmental spectrum. Aim 2(a) will then determine the cord blood proteome signatures of infants with confirmed EOS (cEOS) and culture-negative presumed sepsis (PS). cEOS will be compared to matched controls to identify differentially expressed proteins and candidate markers. PS proteomes will be analyzed to help delineate true infection versus inflammatory subtypes in this heterogeneous group. Bioinformatics pathway analysis may provide novel insights into fetal immune response. Aim 2(b) will determine the best combination of markers to exclude EOS through machine learning decision analysis of proteomics data. Paired placental proteomics in Aim 2(c) will explore origins of fetal inflammation. Aim 3(a) will quantify candidate proteins by an orthogonal immunoassay method. In a validation set of new subjects, Aim 3(b) will measure candidate markers by targeted proteomics and test application of the proposed diagnostic tool. With formal didactics and a mentorship team at Northwestern University with expertise in prematurity, sepsis, biomarker discovery, biostatistics, and decision modeling led by Patrick Seed MD Ph.D., the candidate will gain advanced translational research experience and skills in perinatal research study design, advanced immunology, proteomics, and bioinformatics to further her research agenda. The proposed research and career development will be fundamental towards achieving the candidate’s career goals to: 1) lead a clinical-translational research program on the pathophysiology and host responses of perinatal infection and 2) bring new, reliable sepsis diagnostics to clinical practice, to improve neonatal outcomes through targeted treatment of EOS and antibiotic stewardship.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2023	ANN & ROBERT H LURIE CHILDRENS HOSPITAL OF CHICAGO	225 E CHICAGO AVE	CHICAGO	IL	60611	COOK	USA	Allergy and Infectious Diseases Research	000	5	6/6/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $189,324 )
2023	2023	ANN & ROBERT H LURIE CHILDRENS HOSPITAL OF CHICAGO	225 E CHICAGO AVE	CHICAGO	IL	60611	COOK	USA	Allergy and Infectious Diseases Research	000	5	12/30/2022	NON-COMPETING CONTINUATION	$189,324
														Subtotal = $189,324

Issue Date FY: 2022 ( Subtotal = $189,864 )
2022	2022	ANN & ROBERT H. LURIE CHILDREN'S HOSPITAL OF CHICAGO	225 E CHICAGO AVE	CHICAGO	IL	60611	COOK	USA	Allergy and Infectious Diseases Research	000	4	1/12/2022	NON-COMPETING CONTINUATION	$189,864
														Subtotal = $189,864

Issue Date FY: 2021 ( Subtotal = $189,432 )
2021	2021	ANN & ROBERT H. LURIE CHILDREN'S HOSPITAL OF CHICAGO	225 E CHICAGO AVE	CHICAGO	IL	60611	COOK	USA	Allergy and Infectious Diseases Research	000	3	1/19/2021	NON-COMPETING CONTINUATION	$189,432
														Subtotal = $189,432

Issue Date FY: 2020 ( Subtotal = $189,950 )
2020	2020	ANN & ROBERT H. LURIE CHILDREN'S HOSPITAL OF CHICAGO	225 E CHICAGO AVE	CHICAGO	IL	60611	COOK	USA	Allergy and Infectious Diseases Research	000	2	1/17/2020	NON-COMPETING CONTINUATION	$189,950
														Subtotal = $189,950

Issue Date FY: 2019 ( Subtotal = $189,432 )
2019	2019	ANN & ROBERT H. LURIE CHILDREN'S HOSPITAL OF CHICAGO	225 E CHICAGO AVE	CHICAGO	IL	60611	COOK	USA	Allergy and Infectious Diseases Research	000	1	2/4/2019	NEW	$189,432
														Subtotal = $189,432

Grand Total All Awards = $948,002

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Molecular Signatures of Early-Onset Neonatal Sepsis in Umbilical Cord Blood

Award Number: K23AI139337

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP

PERIOD OF PERFORMANCE START DATE: 02/04/2019

PERIOD OF PERFORMANCE END DATE: 01/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer